GlassScriptPhysician profile
Jamie Lynn Steele
NPI 1366933079
$7,733.38
in general payments reported to CMS, 2019-2025
54 companies · $2,758 in 2025
The $2,758 reported for 2025 was more than what 96% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,172 · 2024: $2,803 · 2025: $2,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,069 · Education: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,069.00 |
| Education | $664.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $556.00 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $473.16 | 2023-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $410.68 | 2023-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $394.04 | 2023-2025 | Jaypirca, Verzenio |
| Pfizer INC. | $393.27 | 2023-2025 | |
| Astellas Pharma US INC | $379.48 | 2023-2025 | Padcev, Vyloy, Xtandi |
| Daiichi Sankyo INC. | $376.98 | 2023-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $372.65 | 2023-2025 | Ninlaro, Fruzaqla, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $356.42 | 2023-2025 | Calquence, Imfinzi, Enhertu |
| Exelixis INC. | $319.76 | 2023-2025 | Cabometyx |
| Sobi, INC | $293.94 | 2023-2025 | |
| Celgene Corporation | $273.30 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $269.68 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $256.18 | 2023-2025 | |
| Abbvie INC. | $254.31 | 2024-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $191.88 | 2023-2025 | Darzalex, Rybrevant, Talvey |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.19 | 2023-2025 | Gilotrif |
| Gilead Sciences, INC. | $147.07 | 2024-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $129.99 | 2023-2025 | Besremi |
| Glaxosmithkline, LLC. | $115.81 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $97.62 | 2023-2025 | |
| Emd Serono, INC. | $92.02 | 2025 | |
| Eisai INC. | $89.43 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $88.13 | 2023-2025 | Ultomiris |
| Kite Pharma, INC. | $87.36 | 2023-2025 | Yescarta |
| Puma Biotechnology, INC. | $86.52 | 2023-2025 | Nerlynx |
| Jazz Pharmaceuticals INC. | $80.62 | 2023-2024 | |
| Genentech USA, INC. | $80.43 | 2023-2024 | Tecentriq, Alecensa, Rozlytrek |
| Sumitomo Pharma America, INC. | $71.95 | 2024-2025 | Orgovyx |
| Agios Pharmaceuticals, INC. | $57.02 | 2023-2024 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $56.98 | 2024 | Rezlidhia, Tavalisse |
| Stemline Therapeutics INC. | $51.74 | 2025 | Orserdu |
| Seagen INC. | $50.74 | 2023 | Tukysa, Padcev, Adcetris |
| Acrotech Biopharma INC. | $46.77 | 2023-2025 | Beleodaq |
| Syndax Pharmaceuticals, INC. | $43.75 | 2025 | |
| Aveo Pharmaceuticals, INC. | $41.86 | 2023 | Fotivda |
| Deciphera Pharmaceuticals INC. | $40.74 | 2023-2024 | Qinlock |
| Pharmacosmos Therapeutics INC. | $36.37 | 2024 | Monoferric |
| Blueprint Medicines Corporation | $35.00 | 2024 | Ayvakit |
| Taiho Oncology, INC. | $34.02 | 2024 | |
| Mirati Therapeutics, INC. | $33.52 | 2023 | Krazati |
| Epizyme, INC. | $33.33 | 2023-2024 | Onivyde |
| Pharmacyclics LLC, An Abbvie Company | $32.67 | 2023 | Epkinly, Imbruvica |
| Beigene USA, INC. | $32.55 | 2025 | Tevimbra |
| Dendreon Pharmaceuticals LLC | $27.60 | 2023 | Provenge |
| Legend Biotech USA INC. | $26.52 | 2025 | Carvykti |
| Geron Corporation | $23.47 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $22.90 | 2025 | |
| Beone Medicines USA, INC. | $22.31 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $20.38 | 2024 | |
| Array Biopharma INC | $19.99 | 2023 | Braftovi, Xalkori, Lorbrena |
| Genmab U.S., INC. | $19.41 | 2023 | Epkinly |
| G1 Therapeutics, INC. | $18.24 | 2023 | Cosela |
| Immunogen, INC. | $17.63 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.